MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ndt/gfaa294

Медицинская библиотека · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.

Agarwal Rajiv, Anker Stefan D, Bakris George, Filippatos Gerasimos, Pitt Bertram, Rossing Peter, Ruilope Luis, Gebel Martin, Kolkhof Peter, Nowack Christina, Joseph Amer, FIDELIO-DKD and FIGARO-DKD Investigators

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).

Для цитирования: Agarwal Rajiv, Anker Stefan D, Bakris George, Filippatos Gerasimos, Pitt Bertram, Rossing Peter, Ruilope Luis, Gebel Martin, Kolkhof Peter, Nowack Christina, Joseph Amer, FIDELIO-DKD and FIGARO-DKD Investigators. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2022. DOI: 10.1093/ndt/gfaa294.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.